To investigate the mechanisms that drive the increased NASH–HCC transition in the preventive anti-PD1 treatment-setting, we treated NASH-affected mice with combinations of treatments. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.